Zydus Lifesciences’ Verapamil Approval Analyzed
Zydus Lifesciences has just gotten the green light from the U.S. Food and Drug Administration (FDA) to sell Verapamil Hydrochloride Extended-Release Tablets. These tablets come in doses of 120 mg, 180 mg, and 240 mg and are a cheaper version of a medicine already used to treat high blood pressure. This approval is a big step because high blood pressure can lead to serious problems like strokes and heart attacks, and this medication helps reduce that risk.
- FDA approved Zydus’ Verapamil tablets for high blood pressure.
- Generic version of Calan SR, providing a more affordable treatment.
- $24.5 million in annual sales projected in the U.S. market.
- Zydus’ approval count now 428, demonstrating consistent growth.
- Company revenue increased 18% YoY, a strong financial indicator.
- Zydus aims to improve people’s health and overall well-being.
The tablets will be made at Zydus’ factory in Baddi, India. Sales data from IQVIA shows that Verapamil ER Tablets are already selling really well, with an expected annual revenue of $24.5 million in the United States. This shows there’s a clear demand for this type of medication.
Zydus already has 428 approvals for medicines, and they’ve been filing for these approvals since 2003. This shows they’re a company that’s constantly working to bring new medicines to people who need them.
Zydus is a large company with over 27,000 employees around the world, and they’re focused on making healthcare better for everyone. In the last quarter, their profits jumped by 38%, and their sales grew by 18%.
The approval of this generic medication highlights Zydus Lifesciences’ commitment to affordable and effective healthcare solutions.
